Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress

~ Closed Initial Public Offering Raising Gross Proceeds of $26.3 Million ~ Surpassed 500 Million Curated Oncology Data Points for Company's RADR® A.I. Platform ~ Advanced Manufacturing Capabilities for LP-300 and LP-184 Trials

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here